Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and ...

With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.

Sun Pharmaceutical Industries Ltd. closed 14.78% below its 52-week high of 1,960.20 rupees, which the company achieved on ...

Cosmo today announced the signing of an agreement to sell “Digital Trust” to its existing customer Tinexta InfoCert, Europe’s largest Certification Authority and a subsidiary of Tinexta S.p.A., a ...

India's obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly's ...

Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...

ProPublica spent 14 months investigating the FDA’s oversight of foreign drugmakers that send medications to the U.S. These ...

The FDA didn’t routinely test the medications for quality problems or use its vast repository of drug-related complaints to ...

Sun Pharmaceutical Industries Ltd. closed 15.88% below its 52-week high of 1,960.20 rupees, which the company reached on September 30th.

Important Announcement. Dear readers, We would like to share some important news with you. After years of bringing you the latest insights, analysis and innovation news from the pharma industries, we ...

India’s largest drugmaker, Sun Pharmaceutical Industries, has appointed Kirti Ganorkar as its new managing director, ...

Ganorkar has been heading India Business at Sun Pharma since June 2019. Under his leadership, the company’s India Business ...